Insight Molecular Diagnostics Inc. (IMDX) Stock Forecast & Price Target
Insight Molecular Diagnostics Inc. · NASDAQ
$4.60-0.10 (-2.13%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Insight Molecular Diagnostics Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $9.00 to $12.00, so the covering firms are broadly aligned. The average target of $10.50 sits 128% above the current $4.60. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.18 next quarter toward $-0.78 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Insight Molecular Diagnostics Inc.
As of Jul, 2 of 2 firms rate IMDX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IMDX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.18
Range $-0.18 – $-0.18 · 1 analysts · -23% YoY
Next period, 1 analysts expect Insight Molecular Diagnostics Inc. to earn $-0.18 a share (range $-0.18 – $-0.18), versus $-0.23 a year earlier. Full-year consensus is $-0.85, growing to $-0.78 the year after.
REVENUE · NEXT QUARTER
$543.9K
Range $300.0K – $940.0K · 1 analysts · +109% YoY
Revenue is expected to reach $543.9K (range $300.0K – $940.0K), +109.2% year-over-year. Full-year consensus is $2.1M, rising to $7.7M next year.
Top analysts covering Insight Molecular Diagnostics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMDX.
#1
Mike Matson
Needham · Rank #204
Buy
$9.00+95.7% to target
Overall win rate
31%
+ Follow
#2
TF
Thomas Flaten
Lake Street
Buy
$12.00+160.9% to target
Coverage
—
+ Follow
IMDX stock forecast FAQ
What is IMDX's average 12-month price target?+
The 2 analysts with a live target average $10.50 for Insight Molecular Diagnostics Inc. over the next 12 months, ranging from a $12.00 high to a $9.00 low.
Is IMDX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IMDX?+
The Street-high target is $12.00 (Lake Street), and the Street-low is $9.00 (Needham). The average of all 2 active targets is $10.50.
How many Wall Street analysts cover IMDX?+
2 analysts have an active rating on Insight Molecular Diagnostics Inc., and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering IMDX?+
Among analysts who currently cover IMDX, Mike Matson of Needham has the strongest overall Quantellect track record (Rank #204). Their current call is Buy with a $9.00 target.
What is Insight Molecular Diagnostics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.18 per share (range $-0.18 – $-0.18) across 1 analysts. Full-year EPS is projected at $-0.85, rising to $-0.78 the following year.
How much revenue is Insight Molecular Diagnostics Inc. expected to report next quarter?+
Consensus revenue is $543.9K (range $300.0K – $940.0K). Full-year revenue is projected at $2.1M, growing to $7.7M next year.
Have analysts been upgrading or downgrading IMDX lately?+
As of Jul, 2 of 2 firms rate IMDX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMDX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
